Supporting MetMAb entry into the clinic with nonclinical pharmacokinetic (PK) and pharmacodynamic (PD) information

被引：2
|
作者：
Xiang, H. [1 ]
Reyes, A. [1 ]
Merchant, M. [2 ]
Bender, B. [3 ]
Jumbe, N. [3 ]
Young, J. [4 ]
Gelzleichter, T. [5 ]
Vaidyanathan, A. [5 ]
Peterson, A. [6 ]
Damico, L. [1 ]
机构：
[1] Genentech Inc, Early Dev PKPD, San Francisco, CA 94080 USA
[2] Genentech Inc, Canc Signaling & Translat Oncol, San Francisco, CA 94080 USA
[3] Genentech Inc, Clin PKPD, San Francisco, CA 94080 USA
[4] Genentech Inc, Assay & Automat Technol, San Francisco, CA 94080 USA
[5] Genentech Inc, Safety Assessment, San Francisco, CA 94080 USA
[6] Genentech Inc, Oncol Clin Sci ECD, San Francisco, CA 94080 USA
来源：
EJC SUPPLEMENTS | 2008年 / 6卷 / 12期
关键词：
D O I：
10.1016/S1359-6349(08)72462-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：167 / 167
页数：1
相关论文
共 50 条
  • [41] PHARMACOKINETIC (PK) AND PHARMACODYNAMIC (PD) BUMETANIDE (B) DOSE-RANGING STUDY IN INFANTS
    SULLIVAN, JE
    WITTE, MK
    YAMASHITA, TS
    BLUMER, JL
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 55 (02) : 179 - 179
  • [42] Pharmacodynamic and pharmacokinetic (PK/PD) pooled modelling of the antihypertensive response to amlodipine in hypertensive cats
    Pelligand, L.
    Bijsmans, E.
    Doig, M.
    Elliott, J.
    JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 2015, 38 : 26 - 27
  • [43] The significance of distribution of pharmacokinetic (PK) and pharmacodynamic (PD) variabilities in determining clinical outcomes.
    Sun, HH
    Parekh, A
    Chatterjee, DJ
    Zhao, HH
    Pelsor, F
    Lazor, J
    Malinowski, H
    Hunt, J
    Lesko, L
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 71 (02) : P75 - P75
  • [44] How pharmacokinetic-pharmacodynamic (PK-PD) parameters influence antibiotic use
    Mazzei, T.
    JOURNAL OF CHEMOTHERAPY, 2006, 18 : 19 - 21
  • [45] The science of erythropoicsis: Quantification of factors influencing response by pharmacokinetic (PK) and pharmacodynamic (PD) modeling
    Jumbe, NL
    Rossi, G
    Heatherington, AC
    Colowick, A
    BLOOD, 2002, 100 (11) : 9B - 9B
  • [46] Are changes in the pharmacokinetic (PK) and pharmacodynamic (PD) properties of antipsychotics able to improve efficacy and safety?
    Luca Pani
    Annals of General Psychiatry, 7 (Suppl 1)
  • [47] Pharmacokinetic-Pharmacodynamic (PK-PD) Model for Tolvaptan in Patients with Hypervolemic Hyponatremia
    Van Wart, Scott
    Shoaf, Susan
    Mallikaarjun, Suresh
    Mager, Donald
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2015, 42 : S76 - S76
  • [48] Pharmacokinetic/pharmacodynamic (PK/PD) Characteristics of Veliparib with and without Temozolomide in Patients with Hematological Malignancies
    Singh, Renu
    Gopalakrishnan, Mathangi
    Kiesel, Brian F.
    Greer, Jacqueline M.
    Karp, Judith E.
    Gojo, Ivana
    Gobburu, Jogarao
    Rudek, Michelle A.
    Beumer, Jan H.
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2015, 42 : S31 - S32
  • [49] The pharmacokinetic and pharmacodynamic (PK/PD) interaction of ifetroban, a TXA(2) receptor antagonist, and heparin
    Liao, W
    Delaney, C
    Jemal, M
    Norton, J
    Uderman, H
    Ford, N
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 59 (02) : PI86 - PI86
  • [50] Pharmacokinetic and Pharmacodynamic Evaluation of Marbofloxacin and PK/PD Modeling against Escherichia coli in Pigs
    Lei, Zhixin
    Liu, Qianying
    Xiong, Jincheng
    Yang, Bing
    Yang, Shuaike
    Zhu, Qianqian
    Li, Kun
    Zhang, Shishuo
    Cao, Jiyue
    He, Qigai
    FRONTIERS IN PHARMACOLOGY, 2017, 8
12345